Abstract:In the title compound, C14H16ClNO2, the cyclo-hexyl ring has a chair conformation. The dihedral angle between the benzene ring and the mean plane of the four planar C atoms of the cyclo-hexyl ring is 45.2 (3)°. The two carbonyl groups are trans to one another, with an O=C-C=O torsion angle of -137.1 (3)°. In the crystal, mol-ecules are linked by N-H⋯O hydrogen bonds forming chains propagating along [001]. A region of disordered electron density, situated near the unit-cell corners, was treated using the SQUEEZE routine in PLATON [Spek (2009 ▶). Acta Cryst. D65, 148-155]. It gave a solvent-accessible void of ca 400 Å(3) for only 21 electrons. It is probably due to traces of the solvent of crystallization and was not taken into account during structure refinement.

(1 R ,2 S ,5 R )-2-Isopropyl-5-methylcyclohexyl 3,5-bis- O -(4-chlorobenzoyl)-2-deoxy-α- D - erythro -ribofuranoside

1r,2s,5r)-2-Isopropyl-5-Methylcyclohexyl 3,5-Bis-O-(4-Chlorobenzoyl)-2-Deoxy-Alpha-D-Erythro-Ribofuranoside

Synthesis and Crystal Structure Characterization of (1R,2R,3R,5S)-3-(3-chlorophenyl)-1-hydroxy-2-methyl-6-phenyl-8-oxa-6-azabicyclo[3.2.1]octan-7-one

(1′S,2′s,5′r)-3-(2-bromopropionyl)-2′-isopropyl-5′-methylspiro[2h-1,3-benzoxazine-2,1′-cyclohexan]-4(3h)-one

(2S,4s)-2-[(s,e)-2-bromo-1-nitromethyl-3-phenylallyl]-4-methylcyclohexanone

2-Acetyl-amino-1,3,4,6-tetra-O-(tri-methyl-silyl)-2-de-oxy-α-d-gluco-pyran-ose.

(1 R ,2 S ,5 R )-2-Isopropyl-5-methylcyclohexyl (2 S ,3 S )-3-phenyloxirane-2-carboxylate

(aR,1R,2S,5R)-5-methyl-2-(1-methyl-1-phenyl-ethyl)cyclohexyl (4-tert-butylcyclohexylidene)-acetate

(1r,2s,5r)-2-Isopropyl-5-Methylcyclohexyl (2s,3s)-3-Phenyloxirane-2-Carboxylate

(1S,3as,4s,7as)-Ethyl 1-Benzyl-2-(4-methoxybenzyl)-6,7-dimethyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1h-isoindole-4-carboxylate Dichloromethane Monosolvate

(1R,4s,8r,9r,12s,13s,14r,16s,17r,19r)-17-[(ethylsulfanyl)methyl]-9,14-dihydroxy-7,7-dimethyl-2,18-dioxo-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecan-19-yl Acetate Acetone Solvate

<i>rac</i>-7-[(2<i>E</i>)-But-2-enoyl]-13-chloro-<i>N</i>-cyclohexyl-7,8-dihydro-5<i>H</i>-isochromeno[4,3-<i>c</i>]phenanthridine-8-carboxamide

(1<i>S</i>,4a<i>R</i>,5<i>S</i>,6<i>S</i>,8a<i>R</i>*)-3-Benzyl-1-methyl-5,6-diphenyl-3,4,4a,5,6,8a-hexahydro-1<i>H</i>-2,3-benzoxazin-4-one

(3ar,6s,7s,7ar)-2-(4-Methoxybenzyl)-7-(4-Nitrophenyl)-6-Phenyl-3a,6, 7,7a-Tetrahydroisoindolin-1-One

Ethyl (4a<i>R</i>,7<i>S</i>,8<i>S</i>,8a<i>S</i>)-1-oxo-7-phenyl-3,4,4a,7,8,8a-hexahydro-1<i>H</i>-isochromene-8-carboxylate

rac-7-[(2E)-But-2-eno-yl]-13-chloro-N-cyclo-hexyl-7,8-dihydro-5H-isochromeno[4,3-c]phenanthridine-8-carboxamide.

(R,S)-Methyl 3-methyl-5-oxo-1-phenylcyclo-hex-3-ene-1-carboxylate

2-(2-Chloro-phen-yl)-N-cyclo-hexyl-2-oxoacetamide.

1-Methyl-3-Trifluoromethyl-5-[(3-Chlorophenyl)Sulfanyl]-1h-Pyrazole-4-Ca Rbaldehyde O-(4-Chlorobenzoyl)Oxime

N-(4-Chlorophenyl)-2-Deoxy-Alpha-L-Ribopyranosylamine

N-(4-Chlorophenyl)-2-deoxy-ÃŽÂ±-l-ribopyranosylamine